Skip to main content

Cancer Immunotherapy group

Current projects led by Karine Breckpot

Cofinancing OZR FWO Hercules MZW - High-parametric single-cell protein profiling in intact tissues

25/02/2022
OZR3913: Cofinancing OZR FWO Hercules MZW - High-parametric single-cell protein profiling in intact tissues

Movahedi, K. , van Grunsven, L. , Rooman, I. , Van Ginderachter, J. , Smolders, I. , Neyns, B. , Vanhaecke, T. , Laoui, D. , Breckpot, K. , De Veirman, K. , Stijlemans, B. , Van...

Exploring the mechanisms of RESponse and RESistance to novel Cancer immunotherapies in tumors Unresponsive to Earlier immune checkpoint inhibition

28/01/2022
FWOEOS18: Exploring the mechanisms of RESponse and RESistance to novel Cancer immunotherapies in tumors Unresponsive to Earlier immune checkpoint inhibition

Neyns, B. , Breckpot, K. & Tuyaerts, S.

1/01/22 → 31/12/25

Project : Fundamental

TITAN: imaging and manipulation of Tumor-Infiltrating T-Cells using Anti-CD3 Nanobodies

08/11/2021
ANI304: TITAN: imaging and manipulation of Tumor-Infiltrating T-Cells using Anti-CD3 Nanobodies

Breckpot, K. & Ceuppens, H.

1/11/21 → 31/10/22

Project : Fundamental

IOF PoC “MOTIF: MOdification of T cells In situ for altered Functionality”

12/01/2021
IOFPOC42: IOF PoC “MOTIF: MOdification of T cells In situ for altered Functionality”

Devoogdt, N. , Breckpot, K. , Meeus, F. , De Groof, T. & De Vlaeminck, Y.

1/01/21 → 31/12/22

Project : Applied

High intensity focused ultrasound and mRNA nanomedicines: a new strategy to induce and boost anti-tumor immunity

22/12/2020
FWOAL1019: High intensity focused ultrasound and mRNA nanomedicines: a new strategy to induce and boost anti-tumor immunity

Breckpot, K.

1/01/21 → 31/12/24

Project : Fundamental

CARGO: advancing chimeric antigen receptor T cell therapy using nanobody-displaying lentiviral vectors.

19/10/2020
FWOSB101: CARGO: advancing chimeric antigen receptor T cell therapy using nanobody-displaying lentiviral vectors.

Meeus, F. & Breckpot, K.

1/11/20 → 31/10/22

Project : Fundamental

Joint R&D 2020: "IMPACT: Invigorating precision Medicine by Predictive imaging of sdAb-based anti-Cancer Theranostics"

14/07/2020
BRGRD44: Joint R&D 2020: "IMPACT: Invigorating precision Medicine by Predictive imaging of sdAb-based anti-Cancer Theranostics"

Keyaerts, M. , Krasniqi, A. , Breckpot, K. & Goyvaerts, C.

1/07/20 → 30/06/23

Project : Applied

Financiering FWO hercules: ERA platform: Extended RNA Analysis platform - version 2.0

16/06/2020
OZR3588: Financiering FWO hercules: ERA platform: Extended RNA Analysis platform - version 2.0

Rooman, I. , Bouwens, L. , Heimberg, H. , Neyns, B. , Vranken, W. , Vanhaecke, T. , Massie, A. , van Grunsven, L. , De Bruyne, E. , De Bundel, D. , Forsyth, R. , Breckpot, K. , Van Dooren, S. , De...

ICON project PERSOMED

04/02/2020
VLAHLT1: ICON project PERSOMED

Breckpot, K. & Thielemans, K.

1/10/19 → 30/09/22

Project : Applied

GEAR: Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)

17/12/2019
IOF3009: GEAR: Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)

Lahoutte, T. , Devoogdt, N. , Keyaerts, M. , Van Ginderachter, J. , Laoui, D. , Raes, G. , Breckpot, K. & Goyvaerts, C.

1/01/20 → 31/12/24...

Smart design nanoParticles to Activate immune Responses against Cancer (SPARC)

16/04/2019
FWOAL934: Smart design nanoParticles to Activate immune Responses against Cancer (SPARC)

Breckpot, K. , Keyaerts, M. , Barbé, K. & De Smedt, S.

1/01/19 → 31/12/22

Project : Fundamental

Prioritization of neoantigens by the combination of in silico search and mass spectrometry.

31/01/2019
ANI216: Prioritization of neoantigens by the combination of in silico search and mass spectrometry.

Thielemans, K. & Breckpot, K.

1/01/19 → 31/12/22

Project : Fundamental

Current projects led by Dr. Cleo Goyvaerts

Creation of a 3D CRiMe scene to unravel Cytotoxic T cell Resistant Mechanisms in NSCLC

Although immunotherapy became a first line treatment option for lung cancer patients, more than 75% of patients do not show any clinical benefit. Hence, there is an urgent need to study and identify novel Cytotoxic T-cell Resistance Mechanisms (CRMs), installed upon immunoediting. Therefore, we propose to develop a dynamic 3D CRM screening assay that combines tumor antigen-specific cytotoxic T-cell killing with RNA sequencing (RNAseq) to enable RNAseq-directed CRISPR-Cas9 mediated functional CRM validation.

Bone marrow niche – lung cancer X-talk: gossip or fatal choice of words?

Tumor infiltrating myeloid cells have been shown to play crucial roles in lung tumor progression next to resistance to (immuno)therapy. Although the bone marrow niche (BMN) represents the main source of myeloid cells, it is heavily understudied in solid cancer patients. Via this interdisciplinary crosstalk (X-talk) project, we aspire to deliver crucial fundamental biological knowledge on the X-talk between progressing lung tumors and the BMN. More specifically, we aim to optimize and apply an innovative 3D platform to study murine, human, and patient-derived lung tumor – BMN X-talk on the single cell level.